A 2006 review linked prenatal and adolescent cannabis exposure to subtle but broad neurodevelopmental outcomes, from specific cognitive weaknesses to later mood and substance use problems, with animal data pointing to plausible brain mechanisms.
Readers interested in how prenatal and adolescent cannabis exposure relates to cognition, mood, and later psychiatric diagnoses, including researchers, educators, and policy analysts focused on youth and perinatal health.
2 windowsthe developmental periods examined: perinatal exposure and adolescence
What the researchers found
Across human observational studies, prenatal exposure through maternal use was associated with small, domain-specific cognitive differences later in life, especially visuospatial skills, along with higher rates of impulsivity, inattention, hyperactivity, depressive symptoms, and substance use disorders. Adolescent use was linked to longer-term difficulties in cognition and mood, elevated risk of schizophrenia, and higher odds of later substance use disorders.
Animal work mapped out potential mechanisms rather than real-world behavior. Perinatal cannabinoid exposure in animal models altered motor control systems, neuroendocrine function, and nociception. Fetal and early-life exposure was reported to affect the development of dopamine and opioid neurotransmitter systems, offering biological pathways that could help explain human associations.
Sex-specific patterns appeared in both human and animal studies, suggesting interactions between cannabinoids and sex hormones during neurodevelopment.
Why it matters
Debates about cannabis and youth often hinge on whether the developing brain is uniquely sensitive. This review helped shape that conversation by organizing early evidence that linked exposure in pregnancy and adolescence to later cognitive and psychiatric outcomes, while also pointing to biological systems in development that cannabinoids could influence.
The numbers in context
- Publication year: 2006, an early synthesis before widespread legalization and high-potency retail markets
- Developmental windows covered: 2 (perinatal, adolescence)
- Human outcomes associated with exposure: visuospatial cognitive deficits, impulsivity/inattention/hyperactivity, depressive symptoms, schizophrenia, substance use disorders
- Animal domains affected: motor control, neuroendocrine function, nociception
How the study worked
This was a narrative review published in 2006 summarizing human observational and animal experimental studies on cannabis exposure during two windows: the perinatal period and adolescence. Human evidence largely came from cohort and cross-sectional designs that measured maternal use during pregnancy or self-reported adolescent use and then assessed later cognitive and psychiatric outcomes. Animal studies investigated how early cannabinoid exposure altered neural development and physiology. No pooled effect sizes or trial counts were reported in the abstract, and sample sizes for included studies were not specified.
Who was studied
Country not specified. Includes human and animal studies.
What this study cannot tell us
This was a narrative review without a formal systematic search or meta-analysis. Human findings were mostly observational and vulnerable to confounding by factors such as tobacco and alcohol co-use, socioeconomic context, and family history. Exposure measurement often relied on self-report with limited detail on dose, potency, or timing. Animal results cannot be assumed to predict human behavior. Effect sizes, sample sizes, and study quality assessments were not reported in the abstract, making it hard to judge the magnitude or reliability of specific associations. The evidence base reflects studies available up to 2006, before current high-potency products and widespread vaping.
How to read the evidence
Rated preliminary: narrative review mixing observational human studies with animal experiments, no pooled estimates, unclear study quality, and substantial potential for confounding in human data.
When this study was published
Published in 2006. Pre-dates today’s higher-potency products, concentrates, and widespread legal markets. Newer studies may report different exposure patterns and more precise controls for confounders.
The bigger picture
The review framed cannabis as a neurodevelopmental exposure rather than only a recreational substance, highlighting windows when the brain may be more vulnerable. It connected human associations to mechanistic clues from animal models, which helps explain why outcomes might cluster around attention, mood, and reward circuits. The synthesis also flagged sex differences, an underexamined dimension in many drug studies. As an early overview, it set up questions that later cohorts and genetic studies have tried to tackle, including how much of the observed risk travels with co-exposures like tobacco and alcohol, baseline family environment, or inherited liability.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Do the human associations persist after rigorous control for co-exposures, socioeconomic factors, and genetic liability?
- Is there a dose–response or potency–response pattern for prenatal or adolescent exposure?
- Which developmental periods are most sensitive within pregnancy and adolescence, and are effects reversible?
- How do sex hormones interact with cannabinoid signaling to produce sex-specific outcomes?
- Do different cannabinoid profiles, including varying THC-to-CBD ratios, track with different neurodevelopmental trajectories?
Common questions
What outcomes were associated with prenatal cannabis exposure?
What about adolescent use?
Does this prove cannabis causes these outcomes?
What did animal studies contribute?
Were there sex differences?
Read the original research
Cannabis and neurodevelopment: implications for psychiatric disorders.
Human psychopharmacology, 21(4), 245-54
Human Psychopharmacology is a peer-reviewed journal focusing on the effects of drugs on human behavior and mental processes.
Citation
Sundram, Suresh. (2006). Cannabis and neurodevelopment: implications for psychiatric disorders.. Human psychopharmacology, 21(4), 245-54.
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)
- Cannabis and Parkinson's Disease: Tremor, Sleep, and Quality of Life